Welcome to our dedicated page for Pactiv Evergreen news (Ticker: $PTVE), a resource for investors and traders seeking the latest updates and insights on Pactiv Evergreen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pactiv Evergreen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pactiv Evergreen's position in the market.
Pactiv Evergreen Inc. (NASDAQ: PTVE) declared a quarterly dividend of $0.10 per share of common stock, approved by the board of directors. The payment will be made on June 14, 2024, to shareholders of record on May 31, 2024.
Pactiv Evergreen Inc. reported solid operating performance despite macro challenges, with net revenues of $1,252 million for Q1 2024 down 13% YoY. Net income was $10 million compared to a loss of $133 million in Q1 2023. Adjusted EBITDA was $168 million, and diluted EPS was $0.04.
